The Food and Drug Administration collectively interviewed 73 principals in charge of pharmaceutical companies

On the 4th, the Sichuan Food and Drug Administration issued the "Provincial Bureau Holds a Collective Meeting on Drug Quality and Safety Warnings", and 73 drug manufacturers in Sichuan province participated in the meeting or the actual controllers or legal representatives, quality leaders, and production leaders.

The original text is as follows:

In order to further strengthen the risk prevention and control of drug production, implement the main responsibility of the enterprise, and keep the bottom line of drug safety, on March 2, the provincial bureau held a collective meeting for drug manufacturers.

At the meeting, the Pharmaceutical Production Supervision Office analyzed the factors affecting the quality of traditional Chinese medicines in the province, notified the province’s drug production unannounced inspections, evaluative random inspections, quality risk reminders, special inspections and complaints and reports, and arranged for deployment.

He Xun pointed out that the newly revised "Drug Administration Law" comprehensively strengthens the punishment.

He Xun emphasized that all enterprises must strictly implement the main responsibility, establish a quality control system for the whole life cycle of product varieties, implement relevant laws, regulations and technical specifications, and implement "one product, one grade" for key varieties; organize production in accordance with the approved production process, and Provisions for the implementation of change procedures; to ensure the authenticity and completeness of batch production records and inspection data.

Participants said that this meeting is not only a warning education meeting, but also a high-quality business training meeting.